Literature DB >> 11390340

Unrecognized pulmonary venous desaturation early after Norwood palliation confounds Gp:Gs assessment and compromises oxygen delivery.

R Taeed1, S M Schwartz, J M Pearl, J L Raake, R H Beekman, P B Manning, D P Nelson.   

Abstract

BACKGROUND: Hemodynamic stability after Norwood palliation often requires manipulation of pulmonary vascular resistance to alter the pulmonary-to-systemic blood flow ratio (Qp:Qs). Qp:Qs is often estimated from arterial saturation (SaO2), a practice based on 2 untested assumptions: constant systemic arteriovenous O2 difference and normal pulmonary venous saturation. METHODS AND
RESULTS: In 12 patients early (</=3 days) after Norwood palliation, simultaneous arterial, superior vena caval (SsvcO2), and pulmonary venous (SpvO2) oximetry was used to test whether SaO2 accurately predicts Qp:Qs. Stepwise multiple regression assessed the contributions of SaO2, SsvcO2, and SpvO2 to Qp:Qs determination. SaO2 correlated weakly with Qp:Qs (R2=0.08, P<0.05). Inclusion of SsvcO2 and SpvO2 improved Qp:Qs prediction accuracy. Pulmonary venous desaturation (SpvO2 <95%) was observed frequently (30%), especially at FiO2 </=0.21, but normalized with higher FiO2 or PEEP in all patients. In 6 patients, FiO2 was increased incrementally from 0.17 to 0.50 to determine whether this was an effective means to manipulate Qp:Qs. Qp:Qs failed to change predictably with increased FiO2. In 5 of 6 patients, however, higher SpvO2 and SaO2 enhanced systemic oxygen delivery, as demonstrated by improvement in oxygen extraction.
CONCLUSIONS: SaO2 correlated poorly with Qp:Qs because of variability in SsvcO2 and SpvO2. A novel observation was that pulmonary venous desaturation occurred frequently early after Norwood palliation but normalized with higher FiO2 or PEEP. Because unrecognized pulmonary venous desaturation confounds p:s assessment and compromises SaO2 and oxygen delivery, judicious use of inspired oxygen and PEEP may be beneficial in selected patients early after Norwood palliation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390340     DOI: 10.1161/01.cir.103.22.2699

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Intensive care course after stage 1 Norwood procedure: are there early predictors of failure?

Authors:  Sylvie Di Filippo; Yichen Lai; Ana Manrique; Franck Pigula; Ricardo Muñoz
Journal:  Intensive Care Med       Date:  2006-11-18       Impact factor: 17.440

2.  Interpretation of the echocardiographic pressure gradient across a pulmonary artery band in the setting of a univentricular heart.

Authors:  Shane M Tibby; Andrew Durward
Journal:  Intensive Care Med       Date:  2007-10-12       Impact factor: 17.440

Review 3.  Balancing a single-ventricle circulation: 'physiology to therapy'.

Authors:  Rohan Magoon; Neeti Makhija; Surendra Kumar Jangid
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-01-02

Review 4.  Hypoplastic left heart syndrome: current considerations and expectations.

Authors:  Jeffrey A Feinstein; D Woodrow Benson; Anne M Dubin; Meryl S Cohen; Dawn M Maxey; William T Mahle; Elfriede Pahl; Juan Villafañe; Ami B Bhatt; Lynn F Peng; Beth Ann Johnson; Alison L Marsden; Curt J Daniels; Nancy A Rudd; Christopher A Caldarone; Kathleen A Mussatto; David L Morales; D Dunbar Ivy; J William Gaynor; James S Tweddell; Barbara J Deal; Anke K Furck; Geoffrey L Rosenthal; Richard G Ohye; Nancy S Ghanayem; John P Cheatham; Wayne Tworetzky; Gerard R Martin
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

5.  Phosphodiesterase Inhibitor-Based Vasodilation Improves Oxygen Delivery and Clinical Outcomes Following Stage 1 Palliation.

Authors:  Kimberly I Mills; Aditya K Kaza; Brian K Walsh; Hilary C Bond; Mackenzie Ford; David Wypij; Ravi R Thiagarajan; Melvin C Almodovar; Luis G Quinonez; Christopher W Baird; Sitaram E Emani; Frank A Pigula; James A DiNardo; John N Kheir
Journal:  J Am Heart Assoc       Date:  2016-11-02       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.